Download full-text PDF

Source

Publication Analysis

Top Keywords

surveillance variant
4
variant strains
4
strains hiv
4
hiv subtype
4
subtype group
4
group hiv-1
4
surveillance
1
strains
1
hiv
1
subtype
1

Similar Publications

Germline Variant With Somatic Amplification in a Woman With Inflammatory Diseases and Myelodysplastic Syndrome.

Ann Intern Med

January 2025

Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.

View Article and Find Full Text PDF

SARS-CoV-2 surveillance and detection in wild, captive, and domesticated animals in Nebraska: 2021-2023.

Front Vet Sci

January 2025

School of Veterinary Medicine and Biomedical Sciences, Nebraska Veterinary Diagnostic Center, University of Nebraska-Lincoln, Lincoln, NE, United States.

Widespread surveillance for SARS-CoV-2 was conducted across wildlife, captive animals in zoological collections, and domestic cats in Nebraska from 2021 to 2023. The goal of this effort was to determine the prevalence, phylogenetic and spatial distribution characteristics of circulating SARS-CoV-2 variants using various diagnostic methodologies that can utilize both antemortem and postmortem samples, which may be required for wildlife such as white-tailed deer. Statewide surveillance testing revealed high variation in SARS-CoV-2 prevalence among species, with white-tailed deer identified as the primary reservoir.

View Article and Find Full Text PDF

Background: Storage of packed red blood cells (RBCs) for transfusion leads to biochemical and morphological changes, increasing hemolysis risk. Urate levels in blood bags at donation contribute to the molecular heterogeneity and hemolytic propensity of stored RBCs. However, studies to date have been underpowered to investigate at scale the contribution of donor demographics and genetics to the heterogeneity in urate levels across donations.

View Article and Find Full Text PDF

Background: We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech).

View Article and Find Full Text PDF

Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): a prospective cohort study.

J Infect

January 2025

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Pandemic Sciences Institute, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute, University of Oxford, Oxford, UK.

Objectives: Evaluation of the safety and humoral immunogenicity of ChAdOx1 nCoV-19 as a fourth dose booster in individuals who have had two initial doses of the vaccine and a third dose of BNT162b2.

Methods: COV009 is a safety follow-up study of volunteers enrolled in the pivotal pre-licensure ChAdOx1 nCoV-19. In this sub-study 149 eligible participants were given a fourth dose of ChAdOx1 nCoV-19.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!